Die Pfizer-Quartalszahlen wurden soeben veröffentlicht. Hier die wichtigsten Eckdaten.
Der Umsatz liegt bei 24,09 Milliarden Dollar (Vorjahresquartal 10,27/für heute erwartet 21,09).
Der Gewinn liegt bei 1,34 Dollar pro Aktie (Vorjahresquartal 0,59/für heute erwartet 1,03).
Man sieht in den Details:
Der Pfizer-Umsatz mit Impfstoffen stieg im letzten Quartal im Jahresvergleich von 1,72 auf 14,58 Milliarden Dollar! Im Juli prognostizierte Pfizer für seinen mit BioNTech produzierten Corona-Impfstoff noch 33,5 Milliarden Dollar Umsatz in 2021. Heute hebt man diese Prognose an auf 36 Milliarden Dollar.
Die Aktie notiert vorbörslich mit +3,8 Prozent.
CEO-Headline-Aussage im Wortlaut:
Dr. Albert Bourla, Chairman and Chief Executive Officer, stated: “While we are proud of our third quarter financial performance, we are even more proud of what these financial results represent in terms of the positive impact we are having on human lives around the world. For example, more than 75% of the revenues we have recorded up through third-quarter 2021 for Comirnaty(1) have come from supplying countries outside the U.S., and we remain on track to achieve our goal of delivering at least two billion doses to low- and middle-income countries by the end of 2022 — at least one billion to be delivered this year and one billion next year, with the possibility to increase those deliveries if more orders are placed by these countries for 2022. One billion of these doses will be supplied to the U.S. government at a not-for-profit price to be donated to the world’s poorest nations at no charge to those countries. Despite all we have been able to accomplish to date, we remain focused on our future, not our past. Our ultimate goal is to help bring this pandemic to an end as quickly as possible, but also to apply the lessons we have learned through our work on the vaccine to all of our therapeutic areas. We look forward to providing future updates on these efforts.”
Kommentare lesen und schreiben, hier klicken
